Abstract

Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Real World Management of Multiple Myeloma in Asia: Treatment Pattern and Cost
Adeline Lin ... Teng Hiang Heng
Blood | VOL. 130
Adeline Lin, et. al.Adeline Lin ... Teng Hiang Heng
25 Jun 2021
Characterization of Atrial Fibrillation and Bleeding Risk Factors in Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Retrospective Cohort Study of Administrative Medical Claims Data in the United States (US)
Nicole Meyer ... Kanti R Rai
Blood | VOL. 126
Nicole Meyer, et. al.Nicole Meyer ... Kanti R Rai
03 Dec 2015
P806 Perianal Crohn’s Disease (pCD): The outcome of 2nd line and 3rd line biologics in perianal Crohn’s disease
U Shani ... N Ben Shabat
Journal of Crohn's and Colitis | VOL. 17
U Shani, et. al.U Shani ... N Ben Shabat
30 Jan 2023
OS05.7.A Absence of severe hematological toxicity during first line treatment predicts low chance on severe toxicity during second line alkylating chemotherapy in glioblastoma
M C M Kouwenhoven ... A N Van Der Vegt
Neuro-Oncology | VOL. 23
M C M Kouwenhoven, et. al.M C M Kouwenhoven ... A N Van Der Vegt
09 Sep 2021
View more papers

More From: AME Clinical Trials Review

Paper Title
Journal
Date
Author
Combination metronomic chemotherapy and immunotherapy in non-small cell lung cancer remains exploratory: the VinMetAtezo trial
Joel W Neal ... Fangdi Sun
AME Clinical Trials Review | VOL. 2
Joel W Neal, et. al.Joel W Neal ... Fangdi Sun
01 Apr 2024
Neoadjuvant osimertinib: a promising therapeutic option for locally advanced EGFR-mutant lung adenocarcinoma
Masaaki Sato ... Shinji Yuhara
AME Clinical Trials Review | VOL. 2
Masaaki Sato, et. al.Masaaki Sato ... Shinji Yuhara
01 Apr 2024
ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
Leonardo Rojas ... Andrés F Cardona
AME Clinical Trials Review | VOL. 2
Leonardo Rojas, et. al.Leonardo Rojas ... Andrés F Cardona
01 Apr 2024
How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?
Charlotte De Bondt ... Paul Van Schil
AME Clinical Trials Review | VOL. 2
Charlotte De Bondt, et. al.Charlotte De Bondt ... Paul Van Schil
01 Apr 2024
View more papers